Form 4: MacroGenics Officer Stephen L. Eck Reports Stock Transactions
SEC Form 4 Filing
Stephen L. Eck, Chief Medical Officer of MacroGenics Inc., reports the acquisition and disposal of common stock and restricted stock units, as well as the grant of employee stock options.
Summary
- On February 8, 2025, Stephen L. Eck, Chief Medical Officer of MacroGenics Inc., reported transactions involving the company's stock.
- These transactions included the acquisition of 11,168 shares of common stock through the vesting of restricted stock units and the disposal of 20,966 shares.
- Additionally, 3,312 shares were disposed of at a price of $2.6.
- Following these transactions, Eck directly owns 17,654 shares of common stock.
- On February 7, 2025, Eck was granted 113,000 employee stock options with an exercise price of $2.6, expiring on February 7, 2035.
- Eck was also granted 19,000 restricted stock units on February 7, 2025.
- After these transactions, Eck beneficially owns 22,332 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by an officer. It doesn't inherently convey positive or negative sentiment, but the disposal of shares could be viewed with slight caution.
Positives
- The grant of employee stock options and restricted stock units to the Chief Medical Officer could be seen as a positive sign, aligning his interests with the long-term success of the company.
Negatives
- The disposal of 20,966 shares of common stock by the Chief Medical Officer could be interpreted negatively by some investors.
Risks
- Executive stock sales can sometimes signal a lack of confidence in the company's future performance, although this is not always the case.
Future Outlook
The restricted stock units will continue to vest annually, potentially leading to future stock acquisitions by the reporting person.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Executive compensation packages often include stock options and restricted stock units to align management's interests with shareholders, a common practice across the biotechnology industry.
- Vesting schedules for RSUs, such as the 33% annual vesting described, are standard in the industry to incentivize long-term commitment.
Stakeholder Impact
- Shareholders may be interested in the trading activity of company insiders as an indicator of management's confidence in the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 02/08/2024 | Reporting person was granted 33,500 restricted stock units, 33% of which vested on February 8, 2025 and 33% of which will vest each year thereafter. |
| 02/07/2025 | Date of grant of employee stock options and restricted stock units. |
| 02/07/2025 | Date of earliest transaction reported. |
| 02/08/2025 | Date of common stock transactions (acquisition and disposal). |
| 02/11/2025 | Date of signature on the report. |
| 02/07/2035 | Expiration date of employee stock options. |
Keywords
Form 4, MacroGenics, MGNX, Stephen L. Eck, Chief Medical Officer, Stock Options, Restricted Stock Units, Beneficial Ownership, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.